Immucell (ICCC) Assets Average (2011 - 2026)
Immucell's (ICCC) quarterly Assets Average came in at $44.1 million in Q4 2025, down 1.44% YoY from $44.8 million in Q4 2024, and down 4.53% on a QoQ basis from $46.2 million in Q3 2025.
Immucell (ICCC) Assets Average (2011 - 2026) Analysis & Trends
Immucell (ICCC) has 15 years of Assets Average data on file, last reported at $44.1 million in Q4 2025.
- Quarterly Assets Average fell 1.44% year-over-year to $44.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44.1 million (down 1.44% YoY) and the FY2025 annual result came in at $43.8 million, down 1.43% from the prior year.
- Assets Average declined to $44.1 million in Q4 2025, from $46.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $46.3 million in Q2 2022 to a low of $40.0 million in Q1 2021.
- A 5-year average of $44.3 million and a median of $44.2 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average advanced 14.0% — and 2023, when it fell 5.99%.
- Tracing ICCC's Assets Average over 5 years: stood at $44.3 million in 2021, then gained by 2.89% to $45.6 million in 2022, then slipped by 3.19% to $44.2 million in 2023, then increased by 1.35% to $44.8 million in 2024, then declined by 1.44% to $44.1 million in 2025.
- The last three Assets Average figures came in at $44.1 million (Q4 2025), $46.2 million (Q3 2025), and $46.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 44.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.58 Mn |
| Dec 31, 2025 | 44.13 Mn |
| Sep 30, 2025 | 46.23 Mn |
| Jun 30, 2025 | 46.17 Mn |
| Mar 31, 2025 | 45.36 Mn |
| Dec 31, 2024 | 44.77 Mn |
| Sep 30, 2024 | 43.15 Mn |
| Jun 30, 2024 | 42.45 Mn |
| Mar 31, 2024 | 43.43 Mn |
| Dec 31, 2023 | 44.18 Mn |
| Sep 30, 2023 | 44.28 Mn |
| Jun 30, 2023 | 43.57 Mn |
| Mar 31, 2023 | 43.99 Mn |
| Dec 31, 2022 | 45.63 Mn |
| Sep 30, 2022 | 46.19 Mn |
| Jun 30, 2022 | 46.34 Mn |
| Mar 31, 2022 | 45.58 Mn |
| Dec 31, 2021 | 44.35 Mn |
| Sep 30, 2021 | 43.98 Mn |
| Jun 30, 2021 | 41.68 Mn |